DSCAM‐AS1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy. (14th November 2018)

• Record Type: Journal Article
• Authors: Sun, Wei; Li, An‐Qi; Zhou, Ping; Jiang, Yi‐Zhou; Jin, Xi; Liu, Yi‐Rong; Guo, Ya‐Jie; Yang, Wen‐Tao; Shao, Zhi‐Ming; Xu, Xiao‐En
• Is Part Of: Cancer medicine. Volume 7:Number 12(2018:Dec.)
• Page Start: 6137
• Page End: 6146
• Publication Date: 2018-11-14
• Subjects: DSCAM‐AS1 -- endocrine therapy -- long noncoding RNA -- luminal breast cancer -- prognostic factor; 616.994005
• DOI: 10.1002/cam4.1603
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: DSCAM‐AS1 is one of the few intensively studied lncRNAs with high specific expression in luminal breast cancer. It is directly regulated by estrogen receptor α (ERα) and plays vital roles in tumor proliferation, invasion, and tamoxifen resistance. However, the detailed function of DSCAM‐AS1 in tumor progression and its clinical significance remain unclear. We reveal that DSCAM‐AS1 regulates cell proliferation and colony formation by inducing the G1/S transition. RNA‐seq analysis demonstrated that DSCAM‐AS1 participates in crucial biological processes, including DNA replication, the G1/S phase transition, sister chromatid cohesion, chromosome segregation, protein localization to the chromosome and DNA recombination. Most importantly, in the retrospectively registered clinical analysis, high expression of DSCAM‐AS1 is a poor prognostic factor in patients with luminal breast cancer treated with endocrine therapy. In conclusion, DSCAM‐AS1 is a promising clinical therapeutic target that may prolong survival of luminal breast cancer patients treated with endocrine therapy. Abstract : We reveal that DSCAM‐AS1 regulates cell proliferation and colony formation by inducing the G1/S transition. RNA‐seq analysis demonstrated that DSCAM‐AS1 participates in crucial biological processes, including DNA replication, the G1/S phase transition, sister chromatid cohesion, chromosome segregation, protein localization to the chromosome and DNA recombination. Most importantly, in the retrospectively registered clinical analysis, high expression of DSCAM‐AS1 is a poor prognostic factor in patients with luminal breast cancer treated with endocrine therapy.